Workers at an Onyx Pharmaceuticals facility in South San Francisco filed out of the building and into a parking lot Wednesday afternoon after employees reported smelling gas.
Just a week after saying it would close a plant in the U.S. and whack 180 jobs, AstraZeneca said that a facility in the U.K. will also close and 250 more jobs will be cut there.
The Cell Therapy Catapult is part of a government program created a couple of years ago to pump up the cell therapy industry in the U.K. The group plans to invest more than $85 million to build a large-scale cell manufacturing facility in Stevenage that companies can contract with for early-stage to commercial work.
Biocon intends to build a new facility in Vizag, India, for manufacturing insulin products. It is a turnabout for the Indian company, which went to Malaysia with its first insulin facility, in part, over concerns that India was falling behind in providing dependable infrastructure to the pharma industry.
Teva Pharmaceuticals has cut $650 million in costs this year but needs to more than double that over the next two as it faces generic competition to its workhorse multiple sclerosis drug Copaxone. A big part of that will be to continue revamping its production network, CEO Erez Vigodman says.
California-based Peregrine Pharmaceuticals says that contract manufacturing revenue was off in its last quarter but demand remains high for its Avid Bioservices unit, and so like a number of contract manufacturers that target biologics, it is adding capacity.
AstraZeneca has been fighting a losing legal battle to protect the patent on its asthma drug Pulmicort Respules, and a plant in Massachusetts will pay part of the price. The U.K. drugmaker says it will close the plant next year, putting 180 workers out of jobs.
Novartis continues the protracted drawdown at its Diovan plant in New York, telling the state nearly two dozen more jobs will be whacked starting at the end of March.
While Puerto Rico has had its share of announced plant closings this year, it has attracted Florida-based Romark Laboratories, which will make a $110 million investment there.
The U.S. arm of Switzerland-based Ferring Pharmaceutical has opened the first phase of a $135 million U.S. campus with the expectation that it will be in commercial production in the first quarter of 2016. It is its first U.S. manufacturing facility.